Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 29 | 2021 | 80 | 9.090 |
Why?
|
| Antiviral Agents | 32 | 2021 | 135 | 7.810 |
Why?
|
| Hepatitis C | 20 | 2022 | 67 | 6.890 |
Why?
|
| Liver Diseases | 14 | 2022 | 41 | 6.140 |
Why?
|
| Hepacivirus | 23 | 2022 | 76 | 4.640 |
Why?
|
| Pregnancy Complications | 8 | 2022 | 55 | 4.010 |
Why?
|
| Liver Transplantation | 9 | 2023 | 80 | 3.960 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2024 | 7 | 2.220 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 27 | 1.930 |
Why?
|
| Liver Cirrhosis | 13 | 2024 | 64 | 1.870 |
Why?
|
| Pregnancy | 13 | 2022 | 405 | 1.740 |
Why?
|
| Ribavirin | 9 | 2016 | 32 | 1.700 |
Why?
|
| Humans | 71 | 2024 | 31070 | 1.580 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2020 | 19 | 1.560 |
Why?
|
| Coinfection | 4 | 2023 | 31 | 1.330 |
Why?
|
| Sulfonamides | 7 | 2020 | 60 | 1.250 |
Why?
|
| Hepatitis B | 5 | 2019 | 20 | 1.230 |
Why?
|
| Interferon-alpha | 5 | 2012 | 68 | 1.200 |
Why?
|
| Liver Neoplasms | 4 | 2022 | 121 | 1.190 |
Why?
|
| Polyethylene Glycols | 5 | 2012 | 59 | 1.190 |
Why?
|
| United States | 19 | 2022 | 2375 | 1.170 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2022 | 33 | 1.170 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2024 | 10 | 1.080 |
Why?
|
| Female | 37 | 2024 | 17018 | 1.070 |
Why?
|
| HIV Infections | 4 | 2021 | 890 | 1.030 |
Why?
|
| Carbamates | 9 | 2020 | 12 | 0.980 |
Why?
|
| Societies, Medical | 3 | 2022 | 191 | 0.960 |
Why?
|
| Quinoxalines | 5 | 2020 | 11 | 0.920 |
Why?
|
| Drug Therapy, Combination | 13 | 2021 | 246 | 0.910 |
Why?
|
| Hepatitis D | 1 | 2023 | 1 | 0.890 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3809 | 0.840 |
Why?
|
| Gastroenterology | 3 | 2017 | 11 | 0.810 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 46 | 0.790 |
Why?
|
| Living Donors | 1 | 2021 | 6 | 0.780 |
Why?
|
| Prejudice | 1 | 2021 | 41 | 0.760 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 31 | 0.710 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 43 | 0.710 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 26 | 0.710 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 135 | 0.710 |
Why?
|
| Benzimidazoles | 3 | 2019 | 11 | 0.700 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 126 | 0.690 |
Why?
|
| Patient Selection | 1 | 2021 | 246 | 0.690 |
Why?
|
| Genotype | 10 | 2017 | 428 | 0.670 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 2 | 0.660 |
Why?
|
| Sofosbuvir | 6 | 2019 | 7 | 0.640 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 6 | 2019 | 7 | 0.640 |
Why?
|
| Viral Load | 5 | 2016 | 196 | 0.630 |
Why?
|
| Obesity | 1 | 2021 | 307 | 0.630 |
Why?
|
| Algorithms | 2 | 2020 | 416 | 0.620 |
Why?
|
| Adult | 21 | 2021 | 8949 | 0.620 |
Why?
|
| Fear | 1 | 2018 | 47 | 0.610 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2019 | 6 | 0.600 |
Why?
|
| Liver | 3 | 2022 | 184 | 0.590 |
Why?
|
| Drugs, Generic | 1 | 2016 | 4 | 0.550 |
Why?
|
| Cyclopropanes | 5 | 2020 | 25 | 0.540 |
Why?
|
| Middle Aged | 21 | 2021 | 10239 | 0.540 |
Why?
|
| Antacids | 1 | 2016 | 1 | 0.540 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 13 | 0.540 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 2 | 0.530 |
Why?
|
| Sustained Virologic Response | 6 | 2021 | 8 | 0.530 |
Why?
|
| Virology | 1 | 2015 | 15 | 0.520 |
Why?
|
| Length of Stay | 2 | 2016 | 339 | 0.480 |
Why?
|
| Liver Function Tests | 3 | 2022 | 26 | 0.480 |
Why?
|
| Patient Readmission | 1 | 2016 | 132 | 0.480 |
Why?
|
| Young Adult | 9 | 2021 | 2063 | 0.470 |
Why?
|
| Mass Screening | 5 | 2021 | 186 | 0.450 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2021 | 434 | 0.450 |
Why?
|
| Prevalence | 3 | 2023 | 500 | 0.440 |
Why?
|
| Preventive Health Services | 1 | 2013 | 15 | 0.440 |
Why?
|
| Male | 23 | 2021 | 16499 | 0.430 |
Why?
|
| Advisory Committees | 1 | 2013 | 34 | 0.430 |
Why?
|
| Prognosis | 5 | 2022 | 924 | 0.430 |
Why?
|
| Heart Failure | 1 | 2016 | 223 | 0.430 |
Why?
|
| Risk Factors | 6 | 2023 | 2593 | 0.430 |
Why?
|
| Periodicals as Topic | 2 | 2023 | 42 | 0.430 |
Why?
|
| Health Policy | 1 | 2013 | 54 | 0.420 |
Why?
|
| Retrospective Studies | 9 | 2024 | 3665 | 0.410 |
Why?
|
| Disease Management | 2 | 2016 | 126 | 0.400 |
Why?
|
| Hepatitis C Antibodies | 2 | 2022 | 7 | 0.400 |
Why?
|
| Lactams, Macrocyclic | 4 | 2019 | 9 | 0.370 |
Why?
|
| Proline | 4 | 2019 | 19 | 0.370 |
Why?
|
| Imidazoles | 4 | 2020 | 73 | 0.360 |
Why?
|
| Recombinant Proteins | 5 | 2012 | 254 | 0.360 |
Why?
|
| Macrocyclic Compounds | 4 | 2019 | 5 | 0.350 |
Why?
|
| RNA, Viral | 4 | 2022 | 162 | 0.350 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 16 | 0.350 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 43 | 0.340 |
Why?
|
| Aged | 14 | 2020 | 10079 | 0.320 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 225 | 0.310 |
Why?
|
| Cost of Illness | 2 | 2023 | 56 | 0.310 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 7 | 0.310 |
Why?
|
| Motivation | 3 | 2023 | 103 | 0.300 |
Why?
|
| Fatty Liver | 2 | 2019 | 31 | 0.290 |
Why?
|
| Cohort Studies | 6 | 2021 | 2045 | 0.290 |
Why?
|
| Anemia | 1 | 2008 | 100 | 0.280 |
Why?
|
| Medication Adherence | 2 | 2019 | 73 | 0.280 |
Why?
|
| Benzofurans | 3 | 2020 | 7 | 0.260 |
Why?
|
| Adolescent | 4 | 2020 | 2403 | 0.250 |
Why?
|
| Graft Rejection | 2 | 2018 | 75 | 0.250 |
Why?
|
| Valine | 4 | 2019 | 11 | 0.240 |
Why?
|
| Drug Interactions | 2 | 2015 | 62 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 149 | 0.230 |
Why?
|
| Incidence | 2 | 2020 | 790 | 0.230 |
Why?
|
| Pyrrolidines | 3 | 2018 | 21 | 0.230 |
Why?
|
| Risk Assessment | 3 | 2018 | 718 | 0.220 |
Why?
|
| Hepatitis Delta Virus | 1 | 2023 | 1 | 0.220 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 11 | 0.220 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 7 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2019 | 1898 | 0.220 |
Why?
|
| Amides | 2 | 2020 | 21 | 0.220 |
Why?
|
| Benzamides | 1 | 2023 | 21 | 0.220 |
Why?
|
| Uracil | 3 | 2019 | 5 | 0.210 |
Why?
|
| Ritonavir | 3 | 2019 | 18 | 0.210 |
Why?
|
| Vaccination | 1 | 2023 | 48 | 0.210 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 8 | 0.210 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2022 | 7 | 0.210 |
Why?
|
| RNA | 1 | 2022 | 38 | 0.210 |
Why?
|
| Chronic Disease | 3 | 2020 | 534 | 0.210 |
Why?
|
| Fibrosis | 1 | 2022 | 39 | 0.200 |
Why?
|
| History, 20th Century | 1 | 2022 | 70 | 0.200 |
Why?
|
| Selection Bias | 1 | 2021 | 10 | 0.200 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 5192 | 0.190 |
Why?
|
| Fertility | 1 | 2021 | 19 | 0.190 |
Why?
|
| Graft Survival | 2 | 2019 | 98 | 0.190 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 4 | 0.190 |
Why?
|
| Leucine | 2 | 2018 | 15 | 0.190 |
Why?
|
| World Health Organization | 1 | 2020 | 19 | 0.190 |
Why?
|
| Tissue Donors | 1 | 2021 | 81 | 0.180 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 12 | 0.180 |
Why?
|
| Anilides | 2 | 2019 | 12 | 0.180 |
Why?
|
| 2-Naphthylamine | 2 | 2019 | 4 | 0.180 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 155 | 0.180 |
Why?
|
| Hemorrhage | 1 | 2020 | 79 | 0.180 |
Why?
|
| Recurrence | 2 | 2011 | 375 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 274 | 0.170 |
Why?
|
| Critical Care | 1 | 2022 | 246 | 0.170 |
Why?
|
| Consensus | 2 | 2021 | 112 | 0.170 |
Why?
|
| Drug and Narcotic Control | 2 | 2016 | 8 | 0.170 |
Why?
|
| Forecasting | 1 | 2019 | 115 | 0.170 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.170 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 71 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2019 | 80 | 0.160 |
Why?
|
| Transplant Recipients | 1 | 2018 | 23 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 1935 | 0.160 |
Why?
|
| Logistic Models | 2 | 2010 | 410 | 0.160 |
Why?
|
| Internationality | 1 | 2018 | 25 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 344 | 0.160 |
Why?
|
| Infant, Newborn | 1 | 2019 | 637 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 443 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2017 | 4 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 22 | 0.140 |
Why?
|
| Time Factors | 3 | 2016 | 1681 | 0.140 |
Why?
|
| Psychometrics | 1 | 2018 | 270 | 0.140 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 2 | 0.140 |
Why?
|
| Patient Participation | 1 | 2017 | 53 | 0.140 |
Why?
|
| Commerce | 1 | 2016 | 13 | 0.140 |
Why?
|
| Canada | 1 | 2016 | 54 | 0.140 |
Why?
|
| Ascites | 1 | 2016 | 5 | 0.140 |
Why?
|
| Safety | 1 | 2016 | 50 | 0.140 |
Why?
|
| Paracentesis | 1 | 2016 | 4 | 0.140 |
Why?
|
| Quality Control | 1 | 2016 | 47 | 0.140 |
Why?
|
| Fraud | 1 | 2016 | 24 | 0.130 |
Why?
|
| Interferons | 1 | 2016 | 14 | 0.130 |
Why?
|
| Eclampsia | 1 | 2016 | 2 | 0.130 |
Why?
|
| HELLP Syndrome | 1 | 2016 | 2 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 8 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 31 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1209 | 0.130 |
Why?
|
| Hospitalization | 2 | 2016 | 336 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1133 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 150 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2015 | 14 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 40 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2015 | 139 | 0.130 |
Why?
|
| Benchmarking | 1 | 2015 | 46 | 0.130 |
Why?
|
| Isoquinolines | 1 | 2015 | 14 | 0.130 |
Why?
|
| Benzazepines | 1 | 2015 | 9 | 0.130 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 2 | 0.130 |
Why?
|
| Comorbidity | 4 | 2018 | 508 | 0.130 |
Why?
|
| Liver Failure | 1 | 2015 | 11 | 0.120 |
Why?
|
| Indoles | 1 | 2015 | 50 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 161 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2017 | 168 | 0.120 |
Why?
|
| Zinc | 1 | 2015 | 36 | 0.120 |
Why?
|
| Phenotype | 1 | 2015 | 379 | 0.120 |
Why?
|
| Hospitalists | 1 | 2014 | 5 | 0.120 |
Why?
|
| Off-Label Use | 1 | 2014 | 7 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 360 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 344 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2014 | 72 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 90 | 0.110 |
Why?
|
| Drug Eruptions | 1 | 2013 | 11 | 0.110 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 15 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 227 | 0.110 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2017 | 9 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2014 | 146 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 46 | 0.100 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 2 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2017 | 68 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 551 | 0.100 |
Why?
|
| Drug Carriers | 1 | 2010 | 8 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2021 | 24 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 226 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 168 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2011 | 135 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2010 | 293 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 586 | 0.080 |
Why?
|
| Fluorenes | 2 | 2019 | 3 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2008 | 82 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 331 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1008 | 0.070 |
Why?
|
| Hospital Costs | 2 | 2016 | 69 | 0.060 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2022 | 2 | 0.050 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2022 | 2 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 10 | 0.050 |
Why?
|
| Pyrroles | 1 | 2022 | 25 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 63 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 54 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 12 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2019 | 15 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 35 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 177 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2018 | 1 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 24 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 203 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 44 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 696 | 0.040 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 2 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2017 | 112 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 52 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 30 | 0.030 |
Why?
|
| Serine Proteases | 1 | 2016 | 6 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2018 | 145 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2016 | 33 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 31 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 62 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 144 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 34 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 42 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 150 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 818 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 152 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 173 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 69 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 143 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 190 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 354 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 273 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 241 | 0.030 |
Why?
|
| Drug Industry | 1 | 2014 | 29 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 407 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 68 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 93 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 150 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 63 | 0.030 |
Why?
|
| Immunoassay | 1 | 2012 | 45 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 830 | 0.020 |
Why?
|
| Probability | 1 | 2012 | 99 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 138 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 997 | 0.020 |
Why?
|